SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products
SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products

By João L. Carapinha

May 26, 2026

SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing unregistered medicines containing semaglutide, ti...
Impact of MDR Software Regulations on Medical Device Innovation
Impact of MDR Software Regulations on Medical Device Innovation
MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen

By João L. Carapinha

May 25, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab), including its subcutaneous formulation KEYTRUDA SC, combined with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment followed b...
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges
The rapid evolution of AI Healthcare Policy is evident in the Health & AI Policy Index (HAPI) snapshot from January 1, 2026, which catalogs 240 policies illustrating swift expansion of artificial intelligence governance across U...
Search By Category
SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products

Latest

SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products

By João L. Carapinha

May 26, 2026

SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing unregistered medicines containing semaglutide, ti...
Impact of MDR Software Regulations on Medical Device Innovation

Latest

Impact of MDR Software Regulations on Medical Device Innovation
MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion

Latest

Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology

Latest

Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion

Global Updates

Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology

Global Updates

Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges

Global Updates

Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges

By João L. Carapinha

May 25, 2026

The rapid evolution of AI Healthcare Policy is evident in the Health & AI Policy Index (HAPI) snapshot from January 1, 2026, which catalogs 240 policies illustrating swift expansion of artificial intelligence governance across U...
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment

Global Updates

Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. This Hepcludex HDV approval addresses a previously unmet need for patients faci...

Upcoming Global Events

Upcoming Events:
June 6-10, 2026 HTAi 2026 Annual Meeting | Istanbul, Turkey Website →
June 9-11, 2026 World Orphan Drug Congress USA | Thomas M. Menino Convention & Exhibition Center, Boston, MA, USA Website →
June 29-30, 2026 GetReal Institute Annual Conference 2026 | Utrecht, Crowne Plaza, The Netherlands Website →

Europe

Impact of MDR Software Regulations on Medical Device Innovation
Impact of MDR Software Regulations on Medical Device Innovation

By João L. Carapinha

May 26, 2026

MDR software regulations under the EU’s Medical Device Regulation (EU 2017/745) are creating heavy operational and financial pressures, according to a survey of 35 SaMD manufacturers listed in the EUDAMED database. Financial burdens hit 88.6 % of respondents at significant or severe levels, while...
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Key Milestone in GBA-PD Therapy Development Achieved with ACTIVATE Study Completion
Bial announced the completion of the treatment period in its Phase 2b ACTIVATE study evaluating BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who carry a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene, referred to as GBA-PD. The 78-week double-blind treatment pha...
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen
Advancements in Perioperative Bladder Cancer Therapy: A Promising New Regimen

By João L. Carapinha

May 25, 2026

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of KEYTRUDA (pembrolizumab), including its subcutaneous formulation KEYTRUDA SC, combined with Padcev (enfortumab vedotin-ejfv) as neoadjuvant treatment followed b...

North America

Innovative Insights into Menstrual Health Monitoring Through Wearable Technology
Innovative Insights into Menstrual Health Monitoring Through Wearable Technology

By João L. Carapinha

May 26, 2026

An analysis of 1.2 million days of data from 2,596 women across 42,759 menstrual cycles demonstrates that cycle length strongly influences the magnitude of fluctuations in cardiorespiratory biometrics, while shorter sleep durations correlate with greater cycle length deviation. Resting heart rate...
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges
Emergence of AI Healthcare Policy Amidst Fragmentation and Governance Challenges

By João L. Carapinha

May 25, 2026

The rapid evolution of AI Healthcare Policy is evident in the Health & AI Policy Index (HAPI) snapshot from January 1, 2026, which catalogs 240 policies illustrating swift expansion of artificial intelligence governance across U...
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
Hepcludex HDV Approval: A Breakthrough in Chronic Hepatitis Delta Treatment
The U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or with compensated cirrhosis. This Hepcludex HDV approval addresses a previously unmet need for patients faci...
Novartis Oncology Advancements: Key Trial Findings and Market Implications
Novartis Oncology Advancements: Key Trial Findings and Market Implications

By HEOR Staff Writer

May 22, 2026

Novartis oncology advancements take center stage as the company prepares to unveil findings from more than 65 abstracts at the upcoming ASCO and EHA meetings. These presentations spotlight progress with Pluvicto, Kisqali, and Scemblix while reinforcing the firm’s commitment to transforming outcom...

Sub-Saharan Africa

SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products
SAHPRA SAPC Regulatory Enforcement: Addressing Unregistered GLP-1 and GIP Products

By João L. Carapinha

May 26, 2026

SAHPRA SAPC regulatory enforcement has intensified following the seizure of all GLP-1 and GIP injectable products at iDexis (Pty) Ltd trading as Sentra Pharmacy. An inspection on 11 May 2026 revealed the facility was manufacturing and distributing unregistered medicines containing semaglutide, ti...
Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications
Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications

By HEOR Staff Writer

May 21, 2026

Substandard medicines in South Africa continue to infiltrate supply chains through informal markets, unlicensed outlets, and online platforms, leaving patients exposed to unregulated weight-loss injections amid stock shortages and high costs for approved options such as Ozempic. Comp...
Transforming Healthcare Value: Strategic Purchasing in South Africa
Transforming Healthcare Value: Strategic Purchasing in South Africa

By João L. Carapinha

May 20, 2026

Strategic Purchasing Healthcare offers a pathway for South Africa’s healthcare system to deliver improved patient outcomes amid constrained resources, where traditional passive purchasing models relying on historical budgets or uncapped fee-for-service payments have fallen short in prioritising e...
Learning from Global Best Practices in Healthcare Pricing Regulation
Learning from Global Best Practices in Healthcare Pricing Regulation
South Africa continues to face persistent challenges in establishing sustainable healthcare pricing regulation mechanisms, as highlighted in the keynote address at the CMS Industry Indaba. Countries including the United Kingdom, Japan, South Korea, and Thailand have implemented structured price-s...